GLI1 and non-small cell lung carcinoma: However, preclinical data revealed that inhibition of Shh–Gli1/2 signaling is known to sensitize NSCLC to TKI treatment, supporting the fact that level of Shh–Gli1/2 signaling during TKI therapy could reflect or influence treatment outcome and patient survival (10).